Dr. Bramham Reddy, M.D.
What this data tells you about Dr. Reddy
Dr. Bramham Reddy is a hematology & oncology in Lufkin, TX, with 19 years in practice. Based on federal Medicare data, Dr. Reddy performed 40,453 Medicare services across 1,877 unique beneficiaries.
Between the years covered by Open Payments, Dr. Reddy received a total of $68,975 from 47 pharmaceutical and/or device companies across 214 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Reddy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 14,300 | $0 | $2 |
| Epoetin alfa injection (Retacrit) for anemia | 12,170 | $6 | $45 |
| Contrast dye for imaging (iodine-based) | 3,705 | $0 | $1 |
| Dexamethasone injection (steroid) | 1,612 | $0 | $5 |
| Blood draw (venipuncture) | 1,252 | $8 | $25 |
| Complete blood count (CBC) with differential | 1,225 | $8 | $65 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,190 | $1 | $52 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 636 | $92 | $849 |
| High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 600 | $0 | $1 |
| Office visit, established patient (30-39 min) | 588 | $95 | $350 |
| Drug injection, under skin or into muscle | 454 | $11 | $65 |
| Injection of additional new drug or substance into vein | 329 | $12 | $80 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 273 | $22 | $205 |
| Administration of chemotherapy into vein, 1 hour or less | 272 | $101 | $550 |
| Advance care planning consultation, first 30 min | 206 | $59 | $145 |
| Chronic care management, first 20 min/month | 198 | $42 | $85 |
| Injection, zoledronic acid, 1 mg | 198 | $7 | $276 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 190 | $49 | $250 |
| Office visit, established patient (20-29 min) | 183 | $59 | $249 |
| Administration of chemotherapy into vein, each additional hour | 104 | $22 | $225 |
| Administration of additional new drug or substance into vein, 1 hour or less | 99 | $50 | $275 |
| Injection, diphenhydramine hcl, up to 50 mg | 82 | $1 | $14 |
| Irrigation of implanted venous access drug delivery device | 77 | $18 | $250 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 49 | $26 | $130 |
| Blood glucose (sugar) measurement using reagent strip | 47 | $5 | $10 |
| Blood glucose (sugar) test performed by hand-held instrument | 47 | $3 | $10 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 46 | $1,192 | $7,154 |
| Unclassified drugs | 45 | $1 | $48 |
| Ct scan of chest with contrast | 43 | $91 | $1,135 |
| CT scan of abdomen and pelvis with contrast | 43 | $216 | $1,800 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 42 | $127 | $650 |
| Office visit, established patient, complex (40-54 min) | 39 | $137 | $450 |
| New patient office visit (45-59 min) | 36 | $122 | $475 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 28 | $1 | $20 |
| New patient office visit, complex (60-74 min) | 24 | $167 | $495 |
| Infusion into a vein for hydration, each additional hour | 21 | $10 | $110 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (75%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 9% for hematology & oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Reddy is a mixed practice specialist, with above-average Medicare volume (top 24% in TX), and high industry engagement (consulting-driven, top 9%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Reddy experienced with iron sucrose injection (venofer)?
Does Dr. Reddy receive payments from pharmaceutical companies?
How do Dr. Reddy's costs compare to other hematology & oncologys in Lufkin?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology